LENZ Therapeutics (LENZ) Insider Management Buys 22,100 Shares
The investment firm L.P. Ra Capital Management has purchased 22,100 shares of LENZ at a price of $6.77 each.
Reviewed by automated data checks against the source filing. How we make and check alerts
L.P. Ra Capital Management bought 22,100 shares of LENZ Therapeutics, Inc. ($LENZ) on June 15, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $LENZ is down 12.2% after 1 week, down 24.7% after 1 month and down 50.7% to date (from the $6.63 close on Jun 15, 2026).
LENZ
LENZ Therapeutics, Inc.
Key Points
- L.P. Ra Capital Management has bought 22,100 shares of LENZ, valued at about $149,000, on June 15, 2026.
- LENZ shares are currently trading at $6.77, well above their 52-week low of $4.00 but far below their 52-week high of $50.40.
- Analysts have mixed views, with Piper Sandler maintaining a Neutral rating and a target of $7.00, while HC Wainwright & Co. reiterates a Buy rating with a $38.00 target.
Get $LENZ trade alerts by text
We text you when insiders, Congress or big funds trade $LENZ. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated LENZ Therapeutics, Inc. alert may contain errors. Disclosures
L.P. Ra Capital Management's New Purchase
L.P. Ra Capital Management has bought 22,100 shares of LENZ (NasdaqGS: LENZ) on June 15, 2026, at a price of $6.77 each. This purchase is valued at approximately $149,000, reflecting a significant commitment to the company.
Insider Buying and Selling at LENZ Therapeutics, Inc.
This purchase by L.P. Ra Capital Management coincides with several insider transactions on the same day. Jeffrey George, Kimberlee Drapkin, Shelley Thunen, James McCollum, and Frederic Guerard each bought 22,100 shares at a price of $0.00, indicating strong insider confidence in LENZ.
How LENZ Stock Has Traded
LENZ shares are currently trading at $6.77, which is higher than their 52-week low of $4.00 but significantly lower than their peak of $50.40. The stock has recently experienced volatility but remains above its 50-day moving average of $5.02. Investors will be watching closely as the company approaches its next earnings date on November 4, 2026.
Analysts Set New Price Targets
On August 12, 2026, Piper Sandler maintained a Neutral rating on LENZ with a target price of $7.00, down from a prior target of $12.00. Meanwhile, HC Wainwright & Co. reiterated a Buy rating on July 7, 2026, with a target price of $38.00, signaling confidence in the company's future prospects. The average target price among analysts is $24.00, based on seven opinions.
What LENZ Does
LENZ Therapeutics, Inc. focuses on developing therapies to improve vision, particularly for conditions like presbyopia. The company's recent insider buying suggests that key stakeholders believe in its potential for growth as it continues to advance its product candidates.
What's Next for LENZ
Investors should keep an eye on LENZ as it approaches its next earnings report on November 4, 2026. The recent insider purchases could indicate positive sentiment about the company's direction. Remember that this 13F filing reflects holdings as of June 15, and positions may have changed since then.
Related Filing Alerts
Source: L.P. Ra Capital Management's Form 4 filing on $LENZ (Jun 15, 2026). Find the original filing: LENZ Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts